N4 Pharma PLC

N4 Pharma Plc is a specialist pharmaceutical company based in London, United Kingdom, that develops nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. Its products include Nuvec, a silica nanoparticle delivery system with an irregular surface structure that traps and protects siRNA/RNA/DNA, and Liptide, a platform for delivering a proprietary siRNA sequence to silence a fibrotic gene. The company is also developing N4 101, an orally delivered inflammation inhibitor in pre-clinical development for inflammatory bowel disease, and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979.